

# How ICER's Missteps Leave Access in Doubt For Atopic Dermatitis Patients

The Institute for Clinical and Economic Review finds new treatments for atopic dermatitis to be cost effective – justifying health plan coverage for the medications. But methodological missteps invite questions about how secure patients' access to the treatments will be.



## Misstep #1 Calculate Treatment's Value Based on Non-existent Price

*Report determines cost effectiveness before one therapy is even priced and available*



## Misstep #2 Undervalue Health Benefit without Long-term Data

*Report evaluates effectiveness though long-term impact data doesn't yet exist – then uses the lack of data to justify reducing the net health benefit from a "B+" to a "C+"*



## Misstep #3 Overlook Crucial Patient Factors

*Report fails to incorporate quality-of-life benefits that matter to patients*



## Misstep #4 Leave Access Subject to Tentative & Incomplete Information

*Report bases analysis on incomplete data, offering tentative findings that may not supply the consistent, long-term access patients need*

**?** Do ICER's findings promise patient access?

**?** Or set patients up for challenges to come?